Demeclocycline HCl Rx
Generic Name and Formulations:
Demeclocycline HCl 150mg, 300mg; tabs.
Various generic manufacturers
Indications for Demeclocycline HCl:
Tetracycline-sensitive infections, including respiratory, genitourinary, skin and skin structure, soft tissues, and those caused by rickettsiae and Mycoplasma pneumoniae; also cholera, psittacosis, plague, shigellosis.
Take with fluids, 1hr before or 2hrs after meals. 150mg 4 times daily or 300mg twice daily. Gonorrhea patients sensitive to penicillin: initially 600mg followed by 300mg every 12hrs for 4 days to a total of 3g.
<8yrs: not recommended. Take with fluids, 1hr before or 2hrs after meals. ≥8yrs: 7–13mg/kg/day divided into 2–4 doses; max 600mg/day.
Renal or hepatic impairment. Monitor blood, renal and hepatic function in long-term use. Avoid sun and UV light. Discontinue if skin erythema occurs. Pregnancy (Cat.D), nursing mothers: not recommended.
Avoid methoxyflurane, photosensitizing agents. May antagonize bactericidal antibiotics; avoid. Reduced absorption with antacids, iron, zinc, calcium, magnesium, dairy products, urinary alkalinizers, other multivalent cations. May reduce effectiveness of oral contraceptives. Monitor prothrombin time with oral anticoagulants.
Photosensitivity, GI upset, rash, blood dyscrasias, increased BUN, hepatotoxicity, C. difficile associated diarrhea, pseudotumor cerebri; rare: esophagitis and esophageal ulceration.
Formerly known under the brand name Declomycin.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- NT-proBNP May Predict Cardiovascular Outcomes in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally